A Phase III, Multicenter, Randomized, Study
Of Atezolizumab Versus Placebo Administered In Combination With Paclitaxel, Carboplatin, And Bevacizumab To Patients With Newly-Diagnosed Stage III Or Stage IV Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer – YO39523, NCT03038100
PURPOSE OF THIS CLINICAL RESEARCH TRIAL
This is a Phase III, global, double-blind, 2-arm randomized study designed to compare the efficacy and safety of atezolizumab + paclitaxel + carboplatin + bevacizumab versus placebo + paclitaxel + carboplatin + bevacizumab. Study participants will have Stage 3 or 4 ovarian cancer (OC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) with macroscopic residual disease postoperatively (i.e., after primary tumor reductive surgery) or who will undergo neoadjuvant therapy followed by interval surgery.
MORE DETAILS ON THIS OVARIAN CANCER TRIAL
16233 / NCT03038100 / Open 8-23-2017